- Home
- TTE vs AMGN Comparison
TTE vs AMGN Comparison
Compare TTE & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTE
- AMGN
- Stock Information
- Founded
- TTE 1924
- AMGN 1980
- Country
- TTE France
- AMGN United States
- Employees
- TTE N/A
- AMGN N/A
- Industry
- TTE Oil & Gas Production
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TTE Energy
- AMGN Health Care
- Exchange
- TTE Nasdaq
- AMGN Nasdaq
- Market Cap
- TTE 143.5B
- AMGN 156.2B
- IPO Year
- TTE 1991
- AMGN N/A
- Fundamental
- Price
- TTE $58.46
- AMGN $277.29
- Analyst Decision
- TTE Buy
- AMGN Buy
- Analyst Count
- TTE 6
- AMGN 20
- Target Price
- TTE $69.42
- AMGN $324.32
- AVG Volume (30 Days)
- TTE 2.1M
- AMGN 3.7M
- Earning Date
- TTE 04-30-2025
- AMGN 05-01-2025
- Dividend Yield
- TTE 5.80%
- AMGN 3.43%
- EPS Growth
- TTE N/A
- AMGN N/A
- EPS
- TTE 6.69
- AMGN 7.56
- Revenue
- TTE $195,610,000,000.00
- AMGN $33,424,000,000.00
- Revenue This Year
- TTE $11.63
- AMGN $7.36
- Revenue Next Year
- TTE N/A
- AMGN $2.30
- P/E Ratio
- TTE $8.29
- AMGN $36.68
- Revenue Growth
- TTE N/A
- AMGN 18.57
- 52 Week Low
- TTE $52.78
- AMGN $253.30
- 52 Week High
- TTE $74.97
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- TTE 46.43
- AMGN 36.23
- Support Level
- TTE $52.78
- AMGN $267.40
- Resistance Level
- TTE $57.36
- AMGN $296.17
- Average True Range (ATR)
- TTE 1.81
- AMGN 12.41
- MACD
- TTE -0.26
- AMGN -2.02
- Stochastic Oscillator
- TTE 46.14
- AMGN 20.78
About TTE TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 1.6 million barrels of liquids and 5.0 billion cubic feet of natural gas per day. At end-2023, reserves stood at 10.6 billion barrels of oil equivalent, 56% of which are liquids. During 2023, it had LNG sales of 44.3 metric tons. The company owns interests in refineries with capacity of nearly 2.0 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. At year-end, its gross installed renewable power generation capacity was 22.4 gigawatts.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.